Efficacy of a single dose of cryopreserved human umbilical cord mesenchymal stromal cells for the treatment of knee osteoarthritis:a randomized, controlled, double-blind pilot study

Simple item page
dc.coverageDOI: 10.1016/j.jcyt.2024.09.005
dc.creatorPico, Omar Amado
dc.creatorEspinoza, Francisco
dc.creatorCádiz, María Ignacia
dc.creatorSossa, Claudia L.
dc.creatorBecerra-Bayona, Silvia M.
dc.creatorSalgado, María C.Canencio
dc.creatorRodríguez, Javier Eduardo Rengifo
dc.creatorCárdenas, Oscar Fabian Valdivieso
dc.creatorCure, Johanna Marcela Quintero
dc.creatorKhoury, Maroun
dc.creatorArango-Rodríguez, Martha L.
dc.date2024
dc.date.accessioned2025-11-18T19:43:51Z
dc.date.available2025-11-18T19:43:51Z
dc.description<p>Background: Knee osteoarthritis (OA) is the most prevalent degenerative musculoskeletal disorder, which is particularly common in older population. While conventional treatments have limited effectiveness, the development of more effective therapeutic strategies is necessary to address this primary source of pain and disability. Umbilical cord mesenchymal stromal cells (UC-MSCs) offer a promising therapeutic approach for treating knee OA. Aim: This randomized, prospective, double-blind and controlled pilot study was carried out to evaluate and compare the safety and therapeutic efficacy of a single intra-articular injection of a standardized product CellistemOA (5 × 10<sup>6</sup> ± 5 × 10<sup>5</sup> UC-MSCs), vs. triamcinolone (a synthetic corticosteroid) (10 mg/mL) in thirty patients with symptomatic knee OA (Kellgren–Lawrence grade II or III). Methods: The outcomes included changes in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) scores based on a Likert scale, numerical rating score (NRS) for pain, Magnetic Resonance Imaging (MRI), and quality of life (SF-36 questionnaire), from baseline and throughout 12-months of follow-up. Results: Patients treated with CellistemOA showed significant improvement in WOMAC score (including the three subscale scores (pain, stiffness and function), NRS in pain, and SF-36 profile from baseline to 12 months (p &lt; 0.05) compared to the triamcinolone group, and no severe adverse events were reported. There were no significant differences in MRI WORMS scores between the two groups. However, patients who received the cellular treatment experienced a significant improvement in their SF-36 profile (p &lt; 0.05). Conclusions: This pilot study revealed that a single dose of CellistemOA is safe and superior to the active comparator in knee OA at 1-year of follow-up, making it a compelling therapeutic alternative to treat symptomatic OA patients.</p>eng
dc.identifierhttps://investigadores.uandes.cl/en/publications/7234826e-6990-4a0c-8368-ea28bcc8c22a
dc.identifier.urihttps://repositorio.uandes.cl/handle/uandes/53103
dc.languageeng
dc.rightsinfo:eu-repo/semantics/restrictedAccess
dc.sourcevol.27 (2024) nr.2 p.188-200
dc.subjectcell therapy
dc.subjectknee osteoarthritis
dc.subjectregenerative medicine
dc.subjectumbilical-cord-derived mesenchymal stromal cells
dc.subjectSDG 3 - Good Health and Well-being
dc.titleEfficacy of a single dose of cryopreserved human umbilical cord mesenchymal stromal cells for the treatment of knee osteoarthritis:a randomized, controlled, double-blind pilot studyeng
dc.typeArticleeng
dc.typeArtículospa
Files
Collections
PURE